GLP-1 Prescribing Rises Among U.S. Children Aged 8–11

What the study measured

A peer-reviewed research brief in Pediatrics examined recorded prescriptions for GLP-1 receptor agonists among U.S. children aged 8–11 with obesity and without diabetes. The researchers used repeated annual retrospective cohorts from Epic Cosmos covering 2019 through 17 June 2026.

Among 3,520,531 children included across the study period, 20,282—0.6%—had a recorded prescription for Saxenda, Wegovy, or Zepbound. That overall study-period percentage and the paper's annual prevalence estimates use different time frames and must not be treated as interchangeable.

Prescribing increased but remained uncommon overall

The paper reported that annual prescribing prevalence increased from 0.03% in 2019 to 9.3% in 2026. The 2026 estimate is an annual measure from the available 2026 data, while 0.6% describes the full study-period population. Clear denominator and time-period labels are essential when comparing the figures.

Recorded prescriptions were more common among older children in the studied age band, girls, children with obesity-related conditions, and children living in less socially vulnerable communities. NYU reported that 93.7% of treated children had severe obesity and 65.2% had at least one obesity-related condition.

What prescribing data cannot show

An electronic prescription order does not prove that a medicine was dispensed, taken, continued, or beneficial. The study did not establish weight change, adverse events, long-term safety, or whether treatment was appropriate for an individual child.

The analysis was observational. It can describe patterns and differences, but it cannot show that a prescription caused an outcome. The participating Epic sites may not represent every U.S. child, clinician, insurance arrangement, or care setting.

Approval and off-label use

The studied medicines have age- and indication-specific regulatory approvals. A prescription outside an approved age or indication is not automatically evidence of poor care, but neither is it proof of benefit or safety. Decisions for a child require a qualified clinician's assessment of health history, development, family context, alternatives, monitoring, and current product labelling.

Why the access pattern matters

Differences by neighbourhood social vulnerability raise questions about access, specialist availability, insurance coverage, and who can obtain newer treatments. The study cannot by itself identify the cause of those differences, but it provides a basis for further research.

How to use this information

This article describes a prescribing study. It does not recommend a medicine for a child or assess whether any current prescription should start, stop, or change. Families should discuss personal questions with a qualified pediatric clinician.

Medical review status: Pending. This source-led article has not yet been reviewed by a MedoPulse clinician.

Educational notice: MedoPulse provides general educational information, not diagnosis, treatment, or individualized medical advice.